Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 11;5(1):ltaf009.
doi: 10.1093/immadv/ltaf009. eCollection 2025.

Therapeutic targeting of tumour-associated macrophage receptors

Rosa Gomes Alves Martins  1 , Mehmet M Tekin  1 , Mark S Cragg  1   2 , Ali Roghanian  1   2
Affiliations
Review

Therapeutic targeting of tumour-associated macrophage receptors

Rosa Gomes Alves Martins et al. Immunother Adv. .

Abstract

Tumour-associated macrophages (TAM) are present in the majority of tumours, where they comprise one of the most abundant cell types, influencing tumour progression, metastasis, therapy resistance, and relapse. Hence, there is a great interest in targeting TAMs to improve and complement anti-cancer treatments. However, further studies are needed to validate the potential of exploiting TAM cell surface markers for cancer immunotherapy. Here, we review the function of TAMs, their involvement in tumorigenesis, metastasis, and therapy resistance. Furthermore, we summarize the current landscape of key TAM cell surface receptors that are being investigated as potential targets for cancer immunotherapy, highlighting the promise and challenges associated with these approaches.

Keywords: immunotherapy; monoclonal antibodies; tumour microenvironment; tumour-associated macrophages.

PubMed Disclaimer

Conflict of interest statement

The authors declare no further financial or other conflicts of interest.

Figures

Figure 1.
Figure 1.
Macrophage polarization is dependent on different environmental cues. Stimuli within the microenvironment allows for differentiation of monocytes into different macrophage states with a particular array of functions. Although macrophages represent a continuum, they can be broadly divided into “M1-like” and “M2-like”, with the latter being further subdivided into M2a, M2b, M2c, and M2d phenotypes. All of these subsets express different cytokines, chemokines, and receptors allowing them to perform different functions. Created in BioRender. Martins, R. (2025) https://biorender.com/v67o359
Figure 2.
Figure 2.
Anti-tumorigenic and pro-tumorigenic functions of TAMs. Tumour-educated macrophages can promote (right) or suppress (left) tumour development, depending on their activation status and environmental cues. Anti-tumour macrophages can induce cancer cell death via secretion of mediators or through direct cellular interactions. On the other hand, pro- tumour TAMs can mediate immunosuppression by secreting factors into the TME and expressing surface molecules that lead to recruitment of Tregs and inhibition of CTLs. In addition, TAMs have been linked to increased invasion and metastasis, angiogenesis/lymphoangiogensis, and resistance to radiotherapy and chemotherapeutics, as well as disease recurrence. Created in BioRender. Martins, R. (2025) https://biorender.com/s36p829
Figure 3.
Figure 3.
Current therapeutic strategies targeting TAM cell surface receptors. The main therapeutic strategies targeting TAM receptors include increasing phagocytic ability (impairing “don’t eat me” signal pathways), repolarization (from pro- to anti-tumour), reducing and decreasing survival and relocation, and immune checkpoint blockade with antibodies to relieve immunosuppression. The process of macrophage-mediated ADCP involves the recognition of tumour cells by therapeutic antibodies, such as rituximab (anti-CD20) and trastuzumab (anti- HER2) which then engage FcγRs on macrophages. Antibodies targeting “don’t eat me” receptors on macrophages (e.g., SIRPα and Siglec-10) or target cells can enhance ADCP and improve immunotherapy responses. Created in BioRender. Martins, R. (2025) https://biorender.com/h79n993
Figure 4.
Figure 4.
Inhibitory leukocyte immunoglobulin-like receptors. LILRs consist of 5 membrane-bound and one soluble LILRB. Of these receptors, LILRB1, LILRB2, LILRB3 and LILRB5 each contain 4 Ig-like extracellular domains, while LILRB4 contains 2 extracellular Ig-like domains. While LILRB1-5 contains 4, 3, 4, 3 and 2 ITIM domains intracellularly, respectively, LILRB2S is not membrane bound and lacks intracellular ITIMs. Created in BioRender. Martins, R. (2025) https://biorender.com/a18o606
See this image and copyright information in PMC

References

    1. Chaib M, Chauhan SC, Makowski L.. Friend or Foe? Recent strategies to target myeloid cells in cancer. Front Cell Dev Biol 2020; 8:351. https://doi.org/ 10.3389/fcell.2020.00351 - DOI - PMC - PubMed
    1. Cassetta L, Pollard JW.. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov 2018; 17(12):887–904. https://doi.org/ 10.1038/nrd.2018.169 - DOI - PubMed
    1. Cassetta L, Pollard JW.. A timeline of tumour-associated macrophage biology. Nat Rev Cancer 2023; 23(4):238–57. https://doi.org/ 10.1038/s41568-022-00547-1 - DOI - PubMed
    1. Monnier M, Paolini L, Vinatier E. et al. Antitumor strategies targeting macrophages: the importance of considering the differences in differentiation/polarization processes between human and mouse macrophages. J ImmunoTher Cancer 2022; 10(10):e005560. https://doi.org/ 10.1136/jitc-2022-005560 - DOI - PMC - PubMed
    1. Geissmann F, Manz MG, Jung S. et al. Development of monocytes, macrophages, and dendritic cells. Science 2010; 327(5966):656–61. https://doi.org/ 10.1126/science.1178331 - DOI - PMC - PubMed

LinkOut - more resources